Altay Therapeutics is a startup based in the United States, 1 tracked investor.
Altay Therapeutics is a company founded in 2019 headquartered in the United States. Brouky records 1 investor associated with the company.
Altay Therapeutics develops oral small molecule inhibitors targeting transcription factors for the treatment of serious diseases such as facioscapulohumeral muscular dystrophy (FSHD), cancer, and chronic inflammatory conditions.
Funding rounds, investor list, risk signals, and comparable startups, all gated to subscribers.